StocksMedium•5 November 2026•
1 min read
Privia Health Raises 2026 Guidance Following 21.9% Growth in Adjusted EBITDA
Key Facts
1Privia Health reported year-to-date Adjusted EBITDA of $114.7 million, a 21.9% increase compared to the prior year period.
2The company raised its full-year 2026 financial guidance for all key financial metrics.
Privia Health reported year-to-date Adjusted EBITDA of $114.7 million, marking a 21.9% increase compared to the prior year period. According to a statement released via GlobeNewswire, the company has raised its full-year 2026 financial guidance for all key financial metrics following strong operational performance through the first nine months of the year.
PRVA closed at $22.4 on November 4, 2026, prior to the release of the third-quarter results. The stock traded between a low of $21.72 and a high of $22.74 during that session, as the upward revision of the annual outlook highlights sustained growth across the company's primary financial indicators.